Compare NRDS & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRDS | ZVRA |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 720.4M | 741.9M |
| IPO Year | 2021 | 2015 |
| Metric | NRDS | ZVRA |
|---|---|---|
| Price | $9.58 | $14.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $15.00 | ★ $23.00 |
| AVG Volume (30 Days) | 722.0K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 68.42 | ★ 159.21 |
| EPS | 0.29 | ★ 0.60 |
| Revenue | ★ $836,600,000.00 | $106,470,000.00 |
| Revenue This Year | $10.13 | $37.27 |
| Revenue Next Year | $7.11 | $53.42 |
| P/E Ratio | $32.69 | ★ $23.28 |
| Revenue Growth | 21.67 | ★ 350.91 |
| 52 Week Low | $7.33 | $7.16 |
| 52 Week High | $16.24 | $14.58 |
| Indicator | NRDS | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 65.82 | 68.07 |
| Support Level | $9.26 | $8.26 |
| Resistance Level | $10.83 | N/A |
| Average True Range (ATR) | 0.32 | 0.59 |
| MACD | 0.15 | 0.05 |
| Stochastic Oscillator | 85.85 | 93.13 |
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. The Company's platform comprises three primary components: Editorial and Content Publishing, Marketplace and Referral Services, and Financial Services. It operates in the United States, Canada, and the United Kingdom.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.